BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...NASDAQ:RTRX) Sparsentan (RE-021) Small molecule dual angiotensin and endothelin receptor antagonist (DARA) FSGS Phase II Dimerix Ltd....
BioCentury | Jan 27, 2017
Financial News

Dimerix completes private placement

...On Jan. 25, renal disease company Dimerix Ltd. (ASX:DXB) raised A$2 million ($1.5 million) through the sale...
...at A$0.006 in a private placement to new and existing investors. Dimerix Ltd. (ASX:DXB), Melbourne, Australia Alicia Parker Dimerix Ltd....
BioCentury | Oct 24, 2016
Clinical News

Propagermanium and irbesartan: Interim Phase II data

...DMX-200 under a special access scheme. Dimerix expects final data from part A in 2H17. Dimerix Ltd....
BioCentury | Sep 28, 2015
Clinical News

Propagermanium and irbesartan: Phase II started

...selected dose for 84 days. Interim data from the first part are expected by mid-2016. Sun Biomedical...
BioCentury | Apr 18, 2011
Company News

Dimerix Biosciences, Takeda deal

...Dimerix and Takeda's Takeda Cambridge Ltd. subsidiary partnered for a second time to use Dimerix's GPCR-Heteromer...
...first research partnership last year. Further terms were not disclosed (see BioCentury, April 26, 2010). Dimerix...
BioCentury | Apr 26, 2010
Company News

Dimerix Biosciences, Takeda deal

...Dimerix and Takeda's Takeda Cambridge Ltd. subsidiary will use Dimerix's GPCR-Heteromer Identification Technology to identify and...
...develop undisclosed G-protein coupled receptor (GPCR) complexes for undisclosed indications. Further terms were not disclosed. Dimerix...
BioCentury | Aug 22, 2005
Product Development

Nanotech in the clinic

...of principle for the contribution of the nanotechnology to the therapeutic outcome. Starpharma and its Dimerix...
Items per page:
1 - 7 of 7
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...NASDAQ:RTRX) Sparsentan (RE-021) Small molecule dual angiotensin and endothelin receptor antagonist (DARA) FSGS Phase II Dimerix Ltd....
BioCentury | Jan 27, 2017
Financial News

Dimerix completes private placement

...On Jan. 25, renal disease company Dimerix Ltd. (ASX:DXB) raised A$2 million ($1.5 million) through the sale...
...at A$0.006 in a private placement to new and existing investors. Dimerix Ltd. (ASX:DXB), Melbourne, Australia Alicia Parker Dimerix Ltd....
BioCentury | Oct 24, 2016
Clinical News

Propagermanium and irbesartan: Interim Phase II data

...DMX-200 under a special access scheme. Dimerix expects final data from part A in 2H17. Dimerix Ltd....
BioCentury | Sep 28, 2015
Clinical News

Propagermanium and irbesartan: Phase II started

...selected dose for 84 days. Interim data from the first part are expected by mid-2016. Sun Biomedical...
BioCentury | Apr 18, 2011
Company News

Dimerix Biosciences, Takeda deal

...Dimerix and Takeda's Takeda Cambridge Ltd. subsidiary partnered for a second time to use Dimerix's GPCR-Heteromer...
...first research partnership last year. Further terms were not disclosed (see BioCentury, April 26, 2010). Dimerix...
BioCentury | Apr 26, 2010
Company News

Dimerix Biosciences, Takeda deal

...Dimerix and Takeda's Takeda Cambridge Ltd. subsidiary will use Dimerix's GPCR-Heteromer Identification Technology to identify and...
...develop undisclosed G-protein coupled receptor (GPCR) complexes for undisclosed indications. Further terms were not disclosed. Dimerix...
BioCentury | Aug 22, 2005
Product Development

Nanotech in the clinic

...of principle for the contribution of the nanotechnology to the therapeutic outcome. Starpharma and its Dimerix...
Items per page:
1 - 7 of 7